Teva Pharmaceutical Industries Limited (NYSE:TEVA) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Thursday.

A number of other equities analysts have also commented on TEVA. Jefferies Group LLC reaffirmed a “hold” rating and issued a $26.00 price objective (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $28.00 price objective (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Sanford C. Bernstein lowered shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $42.00 to $28.00 in a research note on Friday, August 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price objective (down previously from $31.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Finally, Maxim Group reaffirmed a “hold” rating and issued a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, July 13th. Five research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $30.91.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 17.62 on Thursday. The firm’s 50 day moving average price is $18.13 and its 200-day moving average price is $28.20. The stock’s market cap is $17.90 billion. Teva Pharmaceutical Industries Limited has a 52 week low of $15.22 and a 52 week high of $51.51.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same period in the prior year, the business posted $1.25 EPS. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. Analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/28/bidaskclub-upgrades-teva-pharmaceutical-industries-limited-teva-to-sell.html.

Several large investors have recently bought and sold shares of TEVA. Stevens Capital Management LP bought a new position in shares of Teva Pharmaceutical Industries Limited during the 1st quarter worth about $328,000. Quantbot Technologies LP bought a new position in shares of Teva Pharmaceutical Industries Limited during the 1st quarter worth about $3,420,000. KBC Group NV increased its holdings in shares of Teva Pharmaceutical Industries Limited by 22.7% during the 1st quarter. KBC Group NV now owns 50,684 shares of the company’s stock worth $1,627,000 after purchasing an additional 9,360 shares during the period. Bristol Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries Limited during the 1st quarter worth about $305,000. Finally, Stifel Financial Corp increased its holdings in shares of Teva Pharmaceutical Industries Limited by 5.3% during the 1st quarter. Stifel Financial Corp now owns 807,391 shares of the company’s stock worth $25,885,000 after purchasing an additional 40,994 shares during the period. Institutional investors own 56.76% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.